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Abstract
Background: Many patients with coronary artery disease (CAD) have overlapping gastroenterological causes of
recurrent chest pain, mainly due to gastroesophageal reflux (GER) and aspirin-induced gastrointestinal tract
damage. These symptoms can be alleviated by proton pump inhibitors (PPIs). The study addressed whether
omeprazole treatment also affects general health-related quality of life (HRQL) in patients with CAD.
Study: 48 patients with more than 50% narrowing of the coronary arteries on angiography without clinically overt
gastrointestinal symptoms were studied. In a double-blind, placebo-controlled, cross-over study design, patients
were randomized to take omeprazole 20 mg bid or a placebo for two weeks, and then crossed over to the other
study arm. The SF-36 questionnaire was completed before treatment and again after two weeks of therapy.
Results: Patients treated with omeprazole in comparison to the subjects taking the placebo had significantly
greater values for the SF-36 survey (which relates to both physical and mental health), as well as for bodily pain,
general health perception, and physical health. In comparison to the baseline values, therapy with omeprazole led
to a significant increase in the three summarized health components: total SF-36; physical and mental health; and
in the following detailed health concept scores: physical functioning, limitations due to physical health problems,
bodily pain and emotional well-being.
Conclusions: A double dose of omeprazole improved the general HRQL in patients with CAD without severe
gastrointestinal symptoms more effectively than the placebo.
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Background
Improvement in health-related quality of life (HRQL) is
an important purpose of medical interventions. The eva-
luation of HRQL is also important for measuring quality
of care and clinical effectiveness, as well as in assessing
reimbursement decisions [1]. HRQL can be assessed
using a number of instruments; they may estimate the
overall (generic) HRQL, for example through the SF-36
questionnaire, as well as using disease-specific question-
naires such as the following: the Quality of Life in Reflux
and Dyspepsia questionnaire (HRQLRAD), the MacNew
Heart Disease Quality of Life instrument, and the quality
of life questionnaire for patients with atrial fibrillation
(AF-HRQL) [2]. The advantage of using a generic HRQL
instrument is the possibility of measuring patients’ over-
all state of health (physical, emotional and social), their
level of general performance, work productivity loss and
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and clinical conditions through HRQL. The most com-
monly used generic HRQL instrument is the SF-36
Health Survey, which evaluates eight main health con-
cepts: physical functioning, bodily pain, role limitations
due to physical health problems, role limitations due to
personal and emotional problems, emotional well-being,
social functioning, energy/fatigue (vitality), and general
health perception, which can be summarized into physi-
cal and mental components [3,4].
Patients with coronary artery disease (CAD) and refrac-
tory or recurrent retrosternal symptoms have a reduction
in life expectancy and HRQL compared to patients with
stable coronary artery disease [4-7]. The causes of this
state are frequently the lack of the possibility of revascu-
larization, atherosclerosis progression, instability of the
subsequent atherosclerotic plaques, or in-stent restenosis
[8], as well as microvascular coronary disease and abnor-
mal cardiac nociception [9]. However, more than 30% of
patients with CAD suffer from persistent chest pain
which is due to extra-cardiac sources overlapping or
mimicking precordial symptoms originating in the heart
[10,11]. These are mainly due to the coexistence of gas-
troesophageal reflux (GER), aspirin-induced gastrointest-
inal tract damage, and musculoskeletal or panic disorders
[4,11-14]. It has been reported that gastrointestinal symp-
toms have a strong negative influence on the physical,
psychological and social functioning in patients with car-
diovascular diseases, requiring the use of acetylosalicylic
acid and the relief of these symptoms, independently of
the kind of therapy, has improved patients’ HRQL [4,15].
Proton pump inhibitors (PPIs) or gastric hydrochloric
acid secretion inhibitors are used in the treatment of
GER, gastric and duodenal ulcer disease, Helicobacter
pylori eradication, in the prevention of gastric and duo-
denal damage during therapy with non-steroidal anti-
inflammatory drugs, and in empirical therapy in the
so-called “omeprazole test”, as the first step in the diag-
nosis of suspected GER-related chest pain [10,11]. In
our previous paper, we demonstrated that the double
dose of omeprazole (2 × 20 mg) recommended as
empirical therapy in patients with CAD significantly
diminished the severity of angina-like chest pain in 35%
of the patients [11]. The present analysis addresses
whether such therapy would improve HRQL as well. To
our knowledge, this is the first paper concerning this
topic.
Method
Forty-eight consecutive outpatients with CAD-11 female
(23%) and 37 male (77%)-diagnosed with recurrent stable
angina-like chest pain refractory to standard anti-angina
therapy and without indications for revascularization
were enrolled in this investigation. The inclusion criteria
were as follows: (1) stable angina-like symptoms for at
least two months prior to the study recurrent in spite of
adequate anti-angina therapy; (2) frequency of chest pain
episodes no fewer than three times per week and a fre-
quency of typical heartburn sensation and other gastroin-
testinal symptoms of no more than once every two weeks
due to dietary indiscretion; (3) at least 50% narrowing of
the coronary vessels in angiography unsuitable for revas-
cularization in the estimation of an interventional cardi-
ologist; lack of epicardial coronary artery spasm during
coronarography; (4) being aged between 40 and 70; and
(5) having given written informed consent regarding
participation in the study. The exclusion criteria were as
follows: (1) lack of consent to study participation; (2)
contraindications for carrying out exercise tests; (3) typi-
cal symptoms of acute or active chronic disease, includ-
ing those of the gastrointestinal tract; (4) any change in
pharmacological treatment for cardiovascular disease
within one month of the start of the study; and (5) the
administration of drugs whic hm a ya f f e c tg a s t r i cs e c r e -
tion or digestive tract motility during the month prior to
the trial (for example PPIs, H2-receptor antagonists,
metoclopramide or cisapride), and/or non-steroidal anti-
inflammatory drugs.
Study protocol
The full design of this single-center study was a rando-
mized double-blind, placebo-controlled, cross-over inves-
tigation (Figure 1) [11,16]. Each patient fulfilling the
inclusion and exclusion criteria was first informed of the
purpose and principles of the study, as well as given an
indication of the prescribed additional drug as being spe-
cific to potentially coexistent GER or aspirin-induced
gastrointestinal tract damage, and not as therapy for the
patient’s CAD. None of the patients refused to take part
in the investigation. Subsequently, an in-depth interview
was carried out with each patient, with special attention
paid to baseline angina and gastrointestinal symptom
intensity and frequency during the 14 days prior to the
start of the study, any therapy undergone and the num-
ber of nitroglycerin tablets taken per day thus far, cardio-
vascular risk factors (hypertension, smoking, alcohol
intake, diabetes mellitus, or a family history of cardiovas-
cular events), and any history of coronary interventions.
Moreover, each subject was asked to complete the SF-36
Health Survey Standard Polish Version 1.0 9/02 for stan-
dard recall (license number: F1-041006-26099). The one
modification to this questionnaire consisted of asking the
patient to evaluate the two-week period prior to the
examination. The original answers obtained to the ques-
tions in the SF-36 questionnaire were re-coded and
scored using the original 0-100 scoring algorithms and
averaged using the respective scale and forms as per
the instructions [3]. Three summarized measures were
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sical health component, and the mental health compo-
nent [3,4]. The first was the sum of all eight health
concept scores; the second, known as the physical health
component, was the sum of the physical components
(role limitations due to personal problems, bodily pain,
and general health scale scores); the third arose from
summarizing the energy/fatigue (vitality), social function-
ing, role limitations due to emotional problems, and
mental health scale scores.
 
Enrollment (n = 48) 
Omeprazole (n = 23) 
20 mg am + 20 mg pm 
for 2 weeks 
Placebo (n = 25) 
1 caps. am + 1 caps. pm 
for 2 weeks 
Inclusion and exclusion criteria verification; 
baseline symptoms assessment; 
completion of the SF-36 Health Survey. 
Kit number assignment according to 
the sequence of study participation. 
Symptom assessment; 
completion of the SF-36 Health Survey 
Block randomization  
at the kit preparation stage. 
Omeprazole (n = 25) 
20 mg am + 20 mg pm 
for 2 weeks 
Placebo (n = 23) 
1 caps. am + 1 caps. pm 
for 2 weeks 
Symptom assessment; 
completion of the SF-36 Health Survey  
Figure 1 Diagram of the randomized double-blind, placebo-controlled cross-over study design.
Budzyński et al. Health and Quality of Life Outcomes 2011, 9:77
http://www.hqlo.com/content/9/1/77
Page 3 of 9Following the baseline examination, each patient was
assigned to the next consecutive drug kit according to
the sequence of his or her participation in this investiga-
tion (Figure 1). Each kit consisted of two boxes (A and B)
with 28 identical-looking capsules containing either
20 mg of omeprazole or the placebo. According to the
random block list generated by the computer at the kit
preparation stage, for every ten kits five in box A (given
first) contained omeprazole and five the placebo. The list
of kit numbers with the respective substance order was
inaccessible to the investigator and patients and was
stored by the kit producer until the end of the study. In
this double-blind fashion, during the first (A) study phase
23 of the subjects obtained omeprazole and 25 the pla-
cebo. Within the second (B) phase patients were crossed
over to the other arm (omeprazole ® placebo or pla-
cebo® omeprazole). A washout period between the two
treatment phases was not applied. The patients were
asked to take capsules for 14 days, twice a day, 30 min-
utes before a meal from their respective box. Patients
took the first dose of the recommended substance on the
evening of the randomization day and the last dose on
the morning of the day of the evaluation. In addition,
patients continued taking stable doses of previously pre-
scribed drugs (i.e. for CAD, hypertension or diabetes
mellitus), including aspirin. Clopidogrel was not recom-
mended for any of the patients. Moreover, no study parti-
cipant changed smoking habits, alcohol drinking status or
lifestyle. The patients were allowed to take short-acting
antacids or nitroglycerin as rescue medication and were
asked to note such events in a diary.
During the study all the patients were asked to com-
plete the study diary assigned to them. They reported
daily the number and severity of chest pain episodes, the
circumstances of the appearance of the pain (e.g. whether
involving effort, rest, stress or night resting), the necessity
for taking nitroglycerin and the number of tablets taken
per day, the presence of heartburn episodes and the need
to take antacid, the appearance of adverse reactions (with
a detailed description), therapy tolerance and the score
for their general feeling in accordance with a 10-point
scale (similar to a visual analog scale). Moreover, at the
end of the investigation phase, the SF-36 questionnaire
was completed and a treadmill stress test performed by
each patient.
Ethics
The study protocol was approved by the local Bioethics
Committee at the Nicolaus Copernicus University, Col-
legium Medicum in Bydgoszcz in Poland. All subjects
gave their written informed consent prior to their inclu-
sion in the study. All procedures were conducted in
compliance with the Declaration of Helsinki.
Statistics
Statistical analysis was conducted using a licensed version
of statistical software STATISTICA PL 9.0 for Windows.
Power considerations indicated that a sample size of at
least 23 persons was required. The results have been pre-
sented as the mean (95% confidence interval or CI) or as
a subject number and percentage. Before the analysis, a
test for the carryover effect of each health concept
defined in the SF-36 survey using a two-stage Grizzle
model was performed. The treatment influence was esti-
mated according to intention-to-treat analysis rules.
However, due to the lack of a washout period, some
doubts as to whether a cross-over design would be
appropriate in HRQL studies, and to exclude potential
carryover effects on data interpretation, the results pre-
sentation has been limited only to those data obtained
from the first investigation phase, as in the randomized
double-blind, placebo-controlled, parallel study design.
To compare the demographic and clinical data pre-
sented in Table 1 Fisher’s exact test (for multiway
tables) and an unpaired Student t-test were used. The
comparisons between groups and study phases were
made using one- and two-factorial ANOVA with two
repetitions. Fisher’s Least Significant Difference (LSD)
post hoc test was used to compare the respective values
of the SF-36 health concepts after the omeprazole and
the placebo phases (Table 2).
Results
Forty-eight patients were included in the study: 23 ran-
domly assigned to therapy with a double dose of ome-
prazole for two weeks to be taken first, and 25 to taking
the placebo first. The two groups did not differ signifi-
cantly in the values for their demographic and clinical
data (Table 1), the only exception being frequent long-
acting nitrate use before the start of the study in
patients taking the placebo first (Table 1).
Patients first treated with omeprazole did not differ sig-
nificantly in baseline SF-36 survey scores in relation to
patients assigned to therapy with the placebo (Table 2). In
comparison to the values obtained for the two-week per-
iod prior to the beginning of the study, the patients treated
with omeprazole at the end of the first phase of the inves-
tigation in comparison to the subjects taking the placebo
had a significantly greater total SF-36 survey score (the
sum of all eight of the health concepts), average values for
bodily pain, general health perception scales, and physical
health summarized into components, being greater by
20%, 35%, 17% and 28% respectively (Table 2).
Discussion
In this analysis, which is restricted to the first phase ori-
ginally performed as a double-blind, placebo-controlled
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d a t i o no fad o u b l ed o s eo fo m e p r a z o l e( 2×2 0m g )n o t
only significantly decreased angina-like chest pain
o c c u r r e n c ei n1 7o ft h e4 8( 3 5 % )p a t i e n t sw i t hC A D
and the prevalence of some electrocardiographic signs
of myocardial ischemia during stress tests, as stated in
our previous work [11], but also improved SF-36 scores.
Subjects randomly assigned to therapy with omeprazole
achieved significantly greater scores than those receiving
the placebo in the total SF-36 survey score and for
scales concerning a summarized physical health compo-
nent, especially those of bodily pain and general health
perception (Table 2). The greatest relative improvement
in SF-36 scores after therapy with omeprazole amounted
to 72% (an absolute difference of 25) on average and
concerned the scale of limitations due to physical health
problems (Table 2). Similar results were shown in the
analysis of the full data obtained from the two crossed-
over phases of the investigation.
The results obtained could be explained only in part by
a decrease in the frequency of acid-related symptom epi-
sodes [11]. Observed improvement in HRQL could also
have resulted from diminishing activation of the neural
cardio-esophageal loop and improvement in myocardial
perfusion due to a decrease in esophageal exposure to
acid [10,11,17-19]. This is suggested by the greater PPI
outcome for physical than for mental health (Table 2).
The third explanation for the observed increase in HRQL
scores which should be considered is a potential addi-
tional decrease in symptoms related to aspirin-induced
Table 1 Demographic and clinical data of the studied subjects (n = 48)
Feature Patients assigned
to therapy with omeprazole
first
(n = 23)
Patients
assigned
to therapy with
the placebo first
(n = 25)
Age (years) 58.3 (55.3-61.2) 61.2 (58.1-62.2)
Gender (males, n, %) 19 (83%) 18 (72%)
Number of angina-like symptoms per week (median and range) 10 (6-35) 12 (6-30)
Number of patients with angina-like symptom severity graded according to CCS
classification
Class II-19 (83%)
Class III-4 (17%)
Class II-17 (68%)
Class III-8 (32%)
Dyslipidemia 21 (91%) 24 (96%)
Concentration of total cholesterol (mg/dl) 198.3 (177-220) 197.9 (182.2-213.5)
Concentration of LDL cholesterol (mg/dl) 118.5 (95.6-141.4) 113.1 (103.2-123.0)
Concentration of HDL cholesterol (mg/dl) 52.6 (46.6-58.6) 50.6 (42.5-58.6)
Concentration of triglycerides (mg/dl) 175.8 (125.6-225.9) 176.9 (125-229)
Hypertension 14 (61%) 11 (44%)
Diabetes mellitus 5 (22%) 9 (36%)
Smoking 7 (30%) 5 (20%)
History of myocardial infarction 13 (57%) 17 (68%)
History of PCI 6 (26%) 11 (44%)
History of CABG 3 (13%) 4 (16%)
Ejection fraction in echocardiography (%) 54.5 (47.2-61.7) 53.8 ± 8.4
Aspirin administration 23 (100%) 25 (100%)
Beta-blocker administration 19 (88%) 25 (100%)
Calcium-blocker administration 7 (30%) 6 (24%)
ACEI administration 20 (87%) 19 (76%)
Number of nitroglycerin tablets taken per week (median and range) 3 (0-20) 3 (0-15)
Long-acting nitrate administration 7 (30%) 15 (60%)*
Statin administration 21 (94%) 24 (96%)
BMI (kg/m
2) 28.4 (26.8-30.0) 28.1 (26.6-29.7)
WHR 0.94 (0.91-0.97) 0.92 (0.89-0.92)
data presented as mean ± 95% CI, or as patient number and %;
*-p < 0.05 between omeprazole and placebo group using Fisher’s exact test (for multiway tables) and the unpaired Student t-test.
PCI-percutaneous coronary intervention; CABG-coronary artery by-pass graft;
BMI-body mass index; WHR-waist to hip (circumference) ratio;
ACEI-angiotensin-converting enzyme inhibitor.
Budzyński et al. Health and Quality of Life Outcomes 2011, 9:77
http://www.hqlo.com/content/9/1/77
Page 5 of 9gastrointestinal tract damage, which may clinically mani-
fest other than as angina-like chest pain. The reported
prevalence of this symptom concerned 61% of the
patients with CAD [20] and had a major impact on
HRQL [4]. However, the high (56%) placebo effect
observed in this study, greater than in the work by van
Rossum et al. [4] (42%), also suggests some additional
role of psychogenic factors in having an impact on
observed changes in HRQL scores. Its potential pathway
for this effect might be explained by a recently reported
omeprazole effect on beta-endorphin plasma level [16].
To our knowledge, the topic of our work has only pre-
viously been taken up in the paper by van Rossum et al.
[4]. In a double-blind placebo-controlled manner, van
Rossum et al. compared the effect of rabeprazole (1 × 20
m g )a n dap l a c e b oo nH R Q La sm e a s u r e db yt h eS F - 3 6
Health Survey in patients with cardiovascular disease
requiring therapy with acetylosalicylic acid, both with
and without gastrointestinal symptoms, two weeks after
Coronary Care Unit discharge. In their study, in contrast
to our investigation, rabeprazole was no better than the
placebo in the improvement of HRQL relating mainly to
gastrointestinal symptom relief. In a multivariate analysis,
van Rossum et al. also did not find any influence of
clinical data on changes in the summarized physical and
mental components of SF-36 scores in responders to
rabeprazole (45%), the placebo (42%) and in non-respon-
ders, although the first group reported a greater HRQL
score than subjects with persistent gastrointestinal symp-
toms. Apparently similar work by Laheij et al. [15] has
been performed according to an observational, non-inter-
ventional study design. Its authors, in analyzing the
impact of gastrointestinal symptoms on the health status
of patients with CAD using the EuroQol (EQ-5D) survey,
showed better self-rated health status in patients using
drugs to manage gastrointestinal symptoms and complete
symptom relief in comparison to subjects who had
decided not to be treated with them. Some discrepancies
in our study with the results of van Rossum et al. [4] and
Laheij et al. [15] might have resulted from differences in
the study design, PPI type and doses, patient numbers
and inclusion criteria, as our patients did not suffer from
clinically manifested gastrointestinal symptoms and
symptoms associated with aspirin use were not analyzed.
As mentioned above, only a few papers have been
published on the topic of PPI impact on HRQL [4,15]
and symptom improvement [11,17] in patients with
CAD. However, the favorable effect of PPIs on HRQL,
Table 2 The values of the respective SF-36 scores in patients randomly treated with omeprazole and the placebo prior
to the study and after two weeks of therapy
SF-36 scales Omeprazole (n = 23) Placebo (n = 25)
At baseline After 2 weeks At baseline After 2 weeks
Total average SF-36 score 53.9
(46.6-61.2)
63.3*#
(56.2-70.4)
50.0
(43.7-56.3)
52.9*
(45.3-60.6)
Physical functioning 63.5
(54.1-72.9)
68.1 #
(57.8-78.3)
56.4
(49.2-63.6)
61.6
(52.9-70.3)
Limitations due to physical health problems 34.8
(15.8-53.7)
59.8#
(39.5-80.1)
35.0
(17.4-52.6)
37.0
(20.7-53.4)
Bodily pain 50.5
(39.8-61.3)
66.6*#
(55.8-77.5)
41.3
(32.8-49.8)
49.4*
(36.2-62.6)
General health perception 45.9
(37.4-54.3)
50.4*
(46.2-54.7)
41.0
(34.5-47.5)
43.0*
(37.1-49.0)
Physical health component (summarized) 48.7
(38.9-58.4)
61.2*#
(52.4-74.4)
43.4
(35.9-50.9)
47.8*
(47.3-66.2)
Limitations due to personal and emotional problems 65.2
(46.5-83.9)
75.4
(60.2-90.6)
60.0
(41.4-78.6)
53.3
(34.7-72.0)
Energy/fatigue (vitality) 52.4
(44.7-60.1)
57.6
(49.8-65.4)
46.4
(40.3-52.5)
52.6#
(44.4-60.8)
Emotional well-being 52.7
(47.9-57.5)
62.3#
(54.8-69.8)
53.9
(49.1-58.8)
57.1
(49.4-64.9)
Social functioning 61.4
(49.8-73.1)
71.2
(60.7-81.7)
64.5
(62.4-76.6)
64.0
(51.3-76.7)
Mental health component (summarized) 57.9
(50.0-65.9)
66.6#
(58.8-74.4)
56.2
(48.6-63.8)
56.8
(47.3-66.2)
data presented as mean and 95% CI.
*-p < 0.05; statistical significance of difference using Fisher’s Least Significant Difference (LSD) post hoc test between omeprazole and placebo groups;
#-statistical significance of difference using Fisher’s Least Significant Difference (LSD) post hoc test for comparing the values at baseline and after respective
therapy.
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generic instruments, has been shown in patients without
cardiovascular diseases but with upper and lower gastro-
intestinal symptoms [21], dyspepsia [22], gastroesopha-
geal reflux disease (GERD) [1,23-29], GER-related
asthma [30], laryngopharyngeal reflux [31], and
for rheumatoid arthritis and arthrosis treated with non-
steroidal anti-inflammatory drugs (NSAIDs) [32]. The
favorable effect of PPIs on many acid-related diseases
was also shown by the exacerbation of GERD symptoms
and impairment of HRQL after their discontinuation,
probably due to acid rebound hypersecretion [23,33].
Our results seem to have some clinical importance.
First, they show the possibility of improving impaired
HRQL in patients with CAD through the treatment of
coexisting but clinically occult gastrointestinal disorders,
not only via a decrease in the severity of symptoms
(GER-related chest pain). It was previously reported that
HRQL in patients with acid-related disorders is as
impaired as that of patients with angina pectoris [34].
Our subjects treated with a double dose of omeprazole
obtained an even greater SF-36 score in such health
scales as limitations due to personal and emotional pro-
blems and the feeling of vitality when these were com-
pared to the mean values reported in the Medical
Outcomes Study [6], with the mean values for the physi-
cal and mental components determined in healthy Cana-
dian and US populations, as well as in other chronic
conditions (e.g. hypertension) [1]. Moreover, the delta of
improvement in some components of the SF-36 score
after therapy with omeprazole observed in our subjects
with CAD was also similar or greater than that seen in
recent studies which evaluated the effect of eight months
of telephone-delivered collaborative care provided for
depressive patients after a coronary artery bypass graft
(CABG) [35] and the influence of GERD symptom disap-
pearance on an increase in SF-36 score [1,29,36].
However, it should be underlined that our results cannot
be applied in all patients with CAD and refractory angina-
like symptoms, mainly because of the questionable but
potentially dangerous interaction between omeprazole and
anti-platelet drugs. This problem was raised by Juurlink
et al. [37], who showed that among patients receiving clo-
pidogrel following acute myocardial infarction, concomi-
tant therapy with PPIs other than pantoprazole was
associated with a loss of beneficial effects of clopidogrel
and an increased risk of reinfarction. Consequently, many
authors have discussed the importance of interactions
between PPIs and clopidogrel [38,39] and aspirin [40,41].
However, the conclusion from a recent systematic review
by Lima and Brophy is that high quality evidence support-
ing a clinically significant clopidogrel and PPI interaction
is presently lacking [39]. In the recent study on Clopido-
grel and the Optimization of Gastrointestinal Events
(COGENT) by Bhatt et al. [42], cardiovascular events were
also no more common with omeprazole, but Juurlink [43]
supports the greater safety of pantoprazole.
Our study has some limitations. Firstly, the sample size
was too low but this did not prevent the reaching of statis-
tical significance in many of the comparisons (Table 2).
Secondly, the patients were not investigated gastroentero-
logically, whereas e.g. GERD type (non-erosive or erosive)
as well as a diagnosis of Helicobacter pylori infection might
affect the PPI therapy outcome [26,27]. However, empirical
therapy with PPIs is an approved gastroenterological diag-
nostic tool for GER-related symptoms, including GER-
related chest pain [14,44], and responders to PPIs do not
need an additional examination if they do not present
warning symptoms. Van Rossum et al. [4] and Laheij et al.
[15] did not examine their patients gastroenterologically
either. Thirdly, the study analysis was performed in a way
other than originally planned but, in our opinion, this can
be justified by the intention to avoid bias due to carryover
effects and to allow a clearer presentation of the results.
Fourthly, patients randomly assigned to therapy with ome-
prazole had only occasionally been treated with long-acting
nitrates (Table 1). This difference may have affected the
investigation outcomes in different ways. On the one hand,
long-acting nitrates are recommended in patients with
greater severity of symptoms. If the symptoms had been
cardiac in origin rather than misdiagnosed GER-related
chest pain, the potential effect of PPIs on symptom severity
and HRQL score might have been less. On the other hand,
long-acting nitrates reduce the severity of angina pectoris
and can induce GER, giving greater probability to achieving
a better self-rated health status. Fifthly, the study was per-
formed with gastric acid secretion inhibitors and was
oriented towards a decrease in acid-related symptom sever-
ity, but specific HRQL questionnaires, e.g. Quality of Life in
Reflux and Dyspepsia, were not used. However, this investi-
gation was performed with patients with CAD and the gas-
troenterological origin of symptoms was not clinically
overt. Therefore, similar to the investigation by van Ros-
sum et al. [4], the greater usefulness of general measures
such as the SF-36 survey was assumed. This commonly
used instrument allows comparisons across conditions and
interventions. Moreover, the assumed inclusion criteria for
patients without severe gastrointestinal manifestation could
not have enabled the demonstration of a significant effect
of omeprazole with the use of a questionnaire oriented to
acid-related disorders. The correction of the decision to
use a generic HRQL survey also justified the statistical sig-
nificance obtained for the differences in this small study
sample. In our opinion, this method demonstrated that the
disadvantages of using the SF-36 survey were fewer than
the advantages.
In conclusion, a double dose of omeprazole improved
the general HRQL in patients with stable CAD who
Budzyński et al. Health and Quality of Life Outcomes 2011, 9:77
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Page 7 of 9were without severe gastrointestinal symptoms more
effectively than the placebo.
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